Abstract Body

Background

British Columbia’s (BC) publicly-funded HIV treatment (HIV Tx) has been available since 1992, and HIV Pre-Exposure Prophylaxis (PrEP) for key populations since 2018. On 1-Dec-2023, a doxycycline for bacterial sexually transmitted infection (b-STI) initiative (Doxy-P) was launched among HIV Tx and PrEP clients, enrolling >3000 clients in 9 months. In light of increasing use of Doxy-P and treatment and its potential impact on antimicrobial resistance (AMR), we examined the prevalence of tetracycline resistance in gonorrhea (GC) cultures in HIV Tx and PrEP clients during various periods of interest.

Methods

We included all PrEP clients, and known or presumed gay, bisexual and other men who have sex with men (gbMSM) and transwomen in HIV Tx, who had ≥1 program prescription dispensed between 1-Jan-2018 and 30-Jun-2024, and ≥1 GC culture and sensitivity ordered between 1-Jan-2017 and 31-Aug-2024. Client tests within 30 days (all specimens, any site) were considered one testing episode (TE). TE’s positive for GC, and tetracycline minimum inhibitory concentrations (MIC) available for GC cultures were described annually and for 5 periods of interest from 1-Jan-2017 through 31-Aug-2024 (Pre-publicly-funded PrEP to Doxy-P scale-up).

Results

Overall, 2,629 clients [98% cismen, 0.8% transwomen, 0.5% ciswomen, 0.3% transmen; with median age 36 (Q1-Q3, 31-43) years] were included. 1998 were PrEP, 605 in HIV Tx, and 26 in PrEP who transitioned to HIV Tx. There were 4143 GC TE’s (range 133-1077 per year), of which 686 (17%) were positive and 528 (77%) had tetracycline MIC values reported (range 9-116 per year). The mean (range) GC tetracycline MIC (mg/L) increased from 2.25 (0.25-16) pre-public PrEP (n=9) to 3.99 (0.06-64) during PrEP scale up (n=206) (See Figure). It then decreased during COVID-19 (n=135) to 1.05 (0.13-32), and remained low during the early Doxy-P period (n=100) at 1.42 (0.06-16). During the first 9 months of Doxy-P scale-up (n=78), the mean GC tetracycline MIC increased to 3.96 (0.13-32), similar to that seen during PrEP scale up.

Conclusions

In this preliminary analysis, a COVID-19 pandemic-related decline in tetracycline resistance rates and levels was observed in GC cultures amongst PrEP and HIV Tx clients, with rates and levels appearing to return to pre-pandemic levels with the introduction of Doxy-P. Close monitoring is warranted, including more routine culture and sensitivity testing for breakthrough cases of GC while on Doxy-P, and on the AMR impacts on off-target organisms.